{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:09Z","timestamp":1791563169950,"version":"4.3.4"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Treatment with chimeric antigen receptor-T (CAR-T) cells has shown promising effectiveness in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL), although the process of preparing for this therapy usually takes a long time. We have recently created CD19 Fast-CAR-T (F-CAR-T) cells, which can be produced within a single day. The objective of this study was to evaluate and contrast the effectiveness and safety of CD19 F-CAR-T cells with those of CD19 conventional CAR-T cells in the management of R\/R B-ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A multicenter, retrospective analysis of the clinical data of 44 patients with R\/R B-ALL was conducted. Overall, 23 patients were administered with innovative CD19 F-CAR-T cells (F-CAR-T group), whereas 21 patients were given CD19 conventional CAR-T cells (C-CAR-T group). We compared the rates of complete remission (CR), minimal residual disease (MRD)-negative CR, leukemia-free survival (LFS), overall survival (OS), and the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Compared with the C-CAR-T group, the F-CAR-T group had significantly higher CR and MRD-negative rates (95.7% and 91.3%, respectively; 71.4% and 66.7%, respectively;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.036 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.044). No significant differences were observed in the 1-year or 2-year LFS or OS rates between the two groups: the 1-year and 2-year LFS for the F-CAR-T group\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      C-CAR-T group were 47.8% and 43.5%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 38.1% and 23.8% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.384 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.216), while the 1-year and 2-year OS rates were 65.2% and 56.5%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 52.4% and 47.6% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.395 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.540). Additionally, among CR patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T-cell therapy, there were no significant differences in the 1-year or 2-year LFS or OS rates: 57.1% and 50.0%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 47.8% and 34.8% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.506 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.356), 64.3% and 57.1%\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 65.2% and 56.5% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.985 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.883), respectively. The incidence of CRS was greater in the F-CAR-T group (91.3%) than in the C-CAR-T group (66.7%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.044). The incidence of ICANS was also greater in the F-CAR-T group (30.4%) than in the C-CAR-T group (9.5%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.085), but no treatment-related deaths occurred in the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compared with C-CAR-T-cell therapy, F-CAR-T-cell therapy has a superior remission rate but also leads to a tolerably increased incidence of CRS\/ICANS. Further research is needed to explore the function of allo-HSCT as an intermediary therapy after CAR-T-cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003479","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T02:00:09Z","timestamp":1753149609000},"page":"2491-2497","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Novel CD19 Fast-CAR-T cells vs. CD19 conventional CAR-T cells for the treatment of relapsed\/refractory CD19-positive B-cell acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"138","author":[{"given":"Xu","family":"Tan","sequence":"first","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi\u2019an, Shaanxi 710032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Haematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command, PLA, Chengdu, Sichuan 610083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Henan Cancer Hospital, Zhengzhou, Henan 450008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanbin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, Yunnan 650032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 311100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"R1-20260407","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-018-0203-8","article-title":"Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia","volume":"54","author":"Craddock","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R2-20260407","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"R3-20260407","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1\u00a0dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"R4-20260407","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2217\/imt-2017-0072","article-title":"CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"9","author":"Liu","year":"2017","journal-title":"Immunotherapy"},{"key":"R5-20260407","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt-2018-0089","article-title":"Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Liu","year":"2019","journal-title":"Immunotherapy"},{"key":"R6-20260407","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/acsptsci.1c00188","article-title":"Enhancing CAR-T cell therapy with functional nucleic acids","volume":"4","author":"Maru","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"R7-20260407","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11596-023-2746-1","article-title":"Donor-derived CD19 CAR-T cells versus chemotherapy plus donor lymphocyte infusion for treatment of recurrent CD19-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Tan","year":"2023","journal-title":"Curr Med Sci"},{"key":"R8-20260407","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: Bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"R9-20260407","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CJI.0000000000000233","article-title":"Donor-derived CAR-T Cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: Case report and review of the literature","volume":"41","author":"Zhang","year":"2018","journal-title":"J Immunother"},{"key":"R10-20260407","doi-asserted-by":"crossref","first-page":"e16498","DOI":"10.1097\/MD.0000000000016498","article-title":"Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R11-20260407","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","article-title":"Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: Results of a pivotal trial","volume":"16","author":"Schubert","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R12-20260407","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti-CD19-CAR-engineered T cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"R13-20260407","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20260407","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R15-20260407","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J"},{"key":"R16-20260407","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"R17-20260407","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-20260407","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2018.08.030","article-title":"The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"R19-20260407","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R20-20260407","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CM9.0000000000002476","article-title":"Challenges and optimal strategies of CAR T therapy for hematological malignancies","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J"},{"key":"R21-20260407","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"key":"R22-20260407","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"R23-20260407","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R24-20260407","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"R25-20260407","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"R26-20260407","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3\u00a0study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"R27-20260407","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"R28-20260407","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/CM9.0000000000002235","article-title":"Current status and prospects of hematopoietic stem cell transplantation in China","volume":"135","author":"Wang","year":"2022","journal-title":"Chin Med J"},{"key":"R29-20260407","doi-asserted-by":"crossref","first-page":"215721","DOI":"10.1016\/j.canlet.2022.215721","article-title":"Unity brings strength: Combination of CAR-T cell therapy and HSCT","volume":"549","author":"Huang","year":"2022","journal-title":"Cancer Lett"},{"key":"R30-20260407","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"R31-20260407","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"R32-20260407","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"R33-20260407","doi-asserted-by":"crossref","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:00:54Z","timestamp":1775592054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003479","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"2024-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}